Harpreet Singh, Ph.D
Chief Scientific Officer
Dr Harpreet Singh co-founded Immatics Biotechnologies GmbH, the parent company of Immatics US, Inc. in 2000 during his PhD studies. Since then he has served over 15 years as Managing Director and Chief Scientific Officer of Immatics GmbH dedicated to the translation of science into highly innovative cancer immunotherapeutics as well as business concepts. At Immatics GmbH, he has led or significantly contributed raising more than $160m of venture capital in four financing rounds from 2004 to 2014 and is responsible for leading >50 FTEs dedicated to Target and TCR Discovery, Immunology, CMC and Translational Development.
Following creation of a business plan for development of adoptive cell therapies based on novel targets and T-cell receptors discovered by Immatics joined with cellular technologies developed by leading scientists at the MD Anderson Cancer Center, Harpreet Singh co-founded Immatics US, Inc. in 2015 raising approx. $20m public funding (CPRIT grant) by the State of Texas.
Trained in chemistry and biochemistry, Harpreet Singh completed his studies with his PhD in immunology at the University of Tuebingen with Hans-Georg Rammensee, a pioneering immunologist who discovered basic principles of all T-cell based immunotherapies – the presentation of peptides by HLA receptors – in the 1990s. Harpreet Singh is inventor on numerous patents and patent applications and has co-authored approx. 30 publications in peer-reviewed journals including Nature Medicine, Nature Biotechnology, Journal of Experimental Medicine, Brain and Blood.